# SecuraBio

Source: https://onco.cc/companies/securabio/  
OnCo record `securabio` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

SecuraBio is a US company that owns the PI3K inhibitor duvelisib (Copiktra), acquired from Verastem in 2020, for relapsed chronic lymphocytic leukaemia and follicular lymphoma.

## Summary

SecuraBio, a privately held company based in Las Vegas, acquired worldwide rights to duvelisib (Copiktra) from Verastem Oncology in 2020. Duvelisib, an oral inhibitor of PI3K-delta and PI3K-gamma, is approved in the United States for relapsed or refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma after two prior therapies; its follicular lymphoma indication was withdrawn in 2021, and the FDA added a boxed warning in 2022 after a survival analysis of the DUO trial. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Secura Bio; Secura Bio, Inc.
- Tags: ctgov-sponsor
- HQ: Las Vegas, NV
- Type: biotech

## Sources

- ClinicalTrials.gov: trials led by SecuraBio: https://clinicaltrials.gov/search?lead=SecuraBio

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- targets: [PI3K delta (PIK3CD)](https://onco.cc/targets/pik3cd/)
- drugs: [Duvelisib](https://onco.cc/drugs/duvelisib/)

---
JSON: https://onco.cc/api/v1/entities/securabio.json